Embla Medical hf Management
Management criteria checks 3/4
Embla Medical hf's CEO is Sveinn Solvason, appointed in Apr 2022, has a tenure of 2.67 years. total yearly compensation is $1.18M, comprised of 48.8% salary and 51.2% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth DKK2.42M. The average tenure of the management team and the board of directors is 2.5 years and 15.9 years respectively.
Key information
Sveinn Solvason
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 48.8% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.5yrs |
| Board average tenure | 15.9yrs |
Recent management updates
Recent updates
Shareholders Should Be Pleased With Embla Medical hf.'s (CPH:EMBLA) Price
Dec 16
Embla Medical hf (CPH:EMBLA) Seems To Use Debt Quite Sensibly
Nov 30Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 25Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Oct 17Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?
Oct 02Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion
Aug 22Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 26Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)
Jul 17Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings
May 14Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 26A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)
Apr 10Is Össur hf (CPH:OSSR) Using Too Much Debt?
Mar 23Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E
Jan 21Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)
Jan 03Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
Nov 28Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Nov 08A Look At The Fair Value Of Össur hf. (CPH:OSSR)
Sep 23We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt
Aug 21Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital
Jul 18Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 14Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
May 19Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively
Mar 14A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)
Jan 21These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well
Dec 22There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital
Dec 07Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?
Sep 21Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Sep 02Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
Aug 16Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price
Jun 16Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends
Jun 01Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?
May 08Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around
Feb 22Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report
Feb 03Calculating The Fair Value Of Össur hf. (CPH:OSSR)
Nov 25Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Oct 17Is Össur hf (CPH:OSSR) A Risky Investment?
Sep 28Calculating The Fair Value Of Össur hf. (CPH:OSSR)
Aug 21Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively
Jul 11Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly
May 28Calculating The Fair Value Of Össur hf. (CPH:OSSR)
May 07There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital
Mar 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$69m |
| Jun 30 2024 | n/a | n/a | US$61m |
| Mar 31 2024 | n/a | n/a | US$57m |
| Dec 31 2023 | US$1m | US$576k | US$58m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$45m |
| Mar 31 2023 | n/a | n/a | US$43m |
| Dec 31 2022 | US$780k | US$409k | US$43m |
Compensation vs Market: Sveinn's total compensation ($USD1.18M) is below average for companies of similar size in the Danish market ($USD1.97M).
Compensation vs Earnings: Sveinn's compensation has increased by more than 20% in the past year.
CEO
Sveinn Solvason (46 yo)
2.7yrs
Tenure
US$1,180,000
Compensation
Mr. Sveinn Solvason had been Chief Financial Officer of Embla Medical hf. (formerly known as ssur hf.) since May 2013 until April 1, 2022 and serves as its President & CEO since April 1, 2022.Mr. Solvaso...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 2.7yrs | US$1.18m | 0.016% DKK 2.4m | |
| Founder | no data | US$25.00k | no data | |
| Chief Financial Officer | 2.3yrs | no data | no data | |
| Chief Operating Officer | 1.5yrs | no data | no data | |
| Investor Relations Director | no data | no data | no data | |
| Executive Vice President of People | no data | US$242.00k | 0.0083% DKK 1.3m | |
| Executive Vice President of Chronic Solutions | no data | US$600.00k | 0.0030% DKK 453.4k | |
| President of Americas | no data | no data | 0.0031% DKK 467.0k | |
| Executive Vice President of Research & Development | 2.7yrs | no data | 0.00014% DKK 21.2k |
2.5yrs
Average Tenure
48yo
Average Age
Experienced Management: EMBLA's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 19.9yrs | US$108.00k | 0.048% DKK 7.2m | |
| Vice Chairman of the Board | 16.9yrs | US$72.00k | no data | |
| Independent Director | 11.8yrs | US$43.00k | 0.0062% DKK 931.0k | |
| Director | 15.9yrs | US$50.00k | no data | |
| Independent Director | 3.8yrs | US$43.00k | no data |
15.9yrs
Average Tenure
67yo
Average Age
Experienced Board: EMBLA's board of directors are seasoned and experienced ( 15.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 04:18 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Embla Medical hf. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Benjamin Silverstone | ABG Sundal Collier Sponsored |
| null null | ABG Sundal Collier Sponsored |